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Abstract
Background: Renal failure in diabetes is mediated by multiple pathways. Experimental and clinical
evidences suggest that renin-angiotensin-aldosterone system (RAAS) has a crucial role in diabetic
kidney disease. A relationship between the RAAS genotypes and chronic renal insufficiency (CRI)
among type 2 diabetes subjects has therefore been speculated. We investigated the contribution
of selected RAAS gene polymorphisms to CRI among type 2 diabetic Asian Indian subjects.
Methods: Twelve single nucleotide polymorphisms (SNPs) from six genes namely-renin (REN),
angiotensinogen (ATG), angiotensin converting enzyme I (ACE), angiotensin II type 1 receptor
(AT1) and aldosterone synthase (CYP11B2) gene from the RAAS pathway and one from chymase
pathway were genotyped using polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) method and tested for their association with diabetic CRI using a case-
control approach. Successive cases presenting to study centres with type 2 diabetes of ≥2 years
duration and moderate CRI diagnosed by serum creatinine ≥3 mg/dl after exclusion of non-diabetic
causes of CRI (n = 196) were compared with diabetes subjects with no evidence of renal disease
(n = 225). Logistic regression analysis was carried out to correlate various clinical parameters with
genotypes, and to study pair wise interactions between SNPs of different genes.
Results: Of the 12 SNPs genotyped, Glu53Stop in AGT and A>T (-777) in AT1 genes, were
monomorphic and not included for further analysis. We observed a highly significant association of
Met235Thr SNP in angiotensinogen gene with CRI (O.R. 2.68, 95%CI: 2.01–3.57 for Thr allele, O.R.
2.94, 95%CI: 1.88–4.59 for Thr/Thr genotype and O.R. 2.68, 95%CI: 1.97–3.64 for ACC haplotype).
A significant allelic and genotypic association of T>C (-344) SNP in aldosterone synthase gene (O.R.
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1.57, 95%CI: 1.16–2.14 and O.R. 1.81, 95%CI: 1.21–2.71 respectively), and genotypic association of
GA genotype of G>A (-1903) in chymase gene (O.R. 2.06, 95%CI: 1.34–3.17) were also observed.
Conclusion: SNPs Met235Thr in angiotensinogen, T>C (-344) in aldosterone synthase, and G>A
(-1903) in chymase genes are significantly associated with diabetic chronic renal insufficiency in
Indian patients and warrant replication in larger sample sets. Use of such markers for prediction of
susceptibility to diabetes specific renal disease in the ethnically Indian population appears promising.
Background
Chronic renal insufficiency (CRI) due to type 2 diabetes is
the leading cause of end-stage renal disease (ESRD)
worldwide. This is one of the most important causes of
premature death among patients with diabetes and a
major health concern. Development of progressive renal
disease is observed in only a proportion (20–30%) of
individuals with type 2 diabetes [1] and familial clustering
(2–4) provide clear evidence for genetic contribution
though causative molecular mechanism(s) are unclear.
High prevalence of diabetic kidney disease without a clear
mode of inheritance even in familial cases cannot be
explained on the basis of polymorphism/mutation in sin-
gle gene but implies a multifactorial origin. Identification
of such genetic determinants would be essential for a pos-
sible early intervention to prevent ESRD.
Candidate genes from various biochemical pathways such
as aldose reductase-polyol, di-acyl glycerol-protein kinase
C, advanced glycosylation-end products (AGE), hex-
osamine pathway and renin-angiotensin-aldosterone sys-
tem (RAAS) have been implicated in the development of
diabetic kidney disease. Of these, the involvement of
RAAS gene polymorphisms in the pathogenesis of dia-
betic kidney disease has been abundantly studied in vari-
ous populations [5-9]. The effector peptide of the RAAS,
angiotensin II (Ang II), is a potent vasoconstrictor and the
increase in intraglomerular pressure caused by Ang II
results in proteinuria and glomerulosclerosis. Thus, all the
genes or genetic loci responsible for excess Ang II produc-
tion or availability are potential candidates for develop-
ment of diabetic kidney disease. These include all the
components of RAAS namely, renin (REN), angiotensino-
gen (AGT), angiotensin-1 converting enzyme (ACE), angi-
otensin II type1 receptor (AT1R) and aldosterone synthase
(CYP11B2). In addition, chymase (CMA), a non RAAS
gene with ACE like activity, also regulates physiological
levels of Ang II. The physiological role of products of each
of the above-mentioned genes in kidney function is well
understood. Of all the markers tested for association with
diabetic kidney disease, ins/del polymorphisms in ACE
and Met235Thr SNP in AGT genes are the two most exten-
sively studied. These polymorphisms are known to con-
trol the circulatory and cellular levels of their respective
gene products [10-12], which in turn could control the
expression of Ang II, providing a link between constitutive
activity of RAAS and development of diabetic kidney dis-
ease.
Asian Indians, an ethnically distinct population, lead the
world in the number of people with type 2 diabetes [13]
and a consequent epidemic of diabetes associated micro-
and macro-vascular complications is inevitable in India.
Though reports on familial clustering of diabetic retinop-
athy and nephropathy [14,15], and a few candidate gene
association studies in type 2 diabetes and diabetic retin-
opathy among Asian Indians are now available [16-18],
very little is known about the susceptibility to diabetic
renal disease, necessitating the present investigation. Con-
sidering the importance of the six genes of RAAS pathway
in the development of diabetic glomerulopathy, associa-
tion of several single nucleotide polymorphisms (SNPs)/
SNP haplotypes in these genes that have been previously
investigated in the other populations have been analysed
with CRI in Indian subjects with type 2 diabetes in the
present study. This is one of the first comprehensive
reports on RAAS pathway gene polymorphisms and dia-
betic renal disease from the Asian Indian population.
Methods
Subjects for the study were recruited at the four participat-
ing medical institutions situated across the country,
namely MS Ramiah Medical College (Bangalore), All
India Institute of Medical Sciences (New Delhi), Jaipur
Diabetes and Research Centre (Jaipur), and Monilek Hos-
pital and Research Centre (Jaipur). Ethical committee
clearance was obtained from the respective medical insti-
tutions prior to the recruitment of subjects in this study.
An informed consent was obtained from all the partici-
pants prior to their recruitment for the study.
Subjects
Consecutive subjects suffering from Type 2 diabetes with
CRI (cases, CRI, n = 196) and diabetics without any evi-
dence of diabetic kidney disease (controls, DM, n = 225)
were recruited from the out-patient departments at the
study centres. Clinical data included information on dura-
tion of diabetes, presence of any complication, history of
other disorders, weight (kg), height (cm), BMI (kg/m2),
systolic and diastolic blood pressure. Documentation of
antidiabetic and antihypertensive medication could not
be obtained for the large majority of patients and henceBMC Medical Genetics 2006, 7:42 http://www.biomedcentral.com/1471-2350/7/42
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these data are not reported. All subjects receiving treat-
ment or those with blood pressure ≥140/≥90 mm Hg were
considered hypertensive in the present study. All patients
underwent either a fundoscopic examination or fluoroan-
giographic study for diagnosis of retinopathy. 10 ml
venous blood was collected from each individual
included in the study for biochemical and genetic analy-
sis. Biochemical analyses to determine fasting glucose,
glycated haemoglobin, serum creatinine, triglycerides,
total cholesterol, and albumin were carried out at the
respective centres using automated analyzer (Konelab 20,
Thermoclinical lab systems, OY Finland) and similar pro-
Table 1: SNPs in RAAS pathway genes, their location, primer sequences, PCR conditions and restriction enzyme with product sizes.
Polymorphism Primer sequence Product size (bp) Annealing temp./Restriction 
enzyme/allele sizes
*REN
C>T (-4063)
Promoter
F: 5'-AAA CTA GAA TGG GCT 
ACC AGA-3'
R: 5'-GCT GTG ACT TGT CTC 
TTC CTG A-3'
235 60°C/Taq I/
C = 163, 68
T = 235
*REN
(ACAG)n
Intron G
F: 5'-ACA GTA CCTT CCC TCC 
TC TAC TCA-3'
R: 5'-CTC TAT GGA GCT GGT 
AGA ACC TGA-3'
255 a1 = 255
2 = 259
3 = 263
4 = 267
5 = 271
*AGT
A>G (-6)
Promoter
F: 5'-CCC TCA GCT ATA AAT 
AGA GCA TC-3'
R: 5'-GCA GGA AGA CCT GAC 
CAT CT-3'
308 61°C/Bst NI/
G = 245, 63
A = 36,209,63
*AGT
Glu53Stop
Exon 2
F: 5'-ACC ATC CTC TGC CTC 
CTG-3'
R: 5'-TCC AAG GCT CCC AGA 
TAG AG-3'
398 58°C/PvuII/
C = 102, 102, 194
T = 204, 194
*AGT
Thr174Met
Exon 2
F: 5'-CAA TTC AGG CCA AGA 
CAT CC-3'
R: 5'-GCC AGA GCC AGC AGA 
GAG-3'
674 58°C/Nco I/
C = 502, 172
T = 256, 246, 172
*AGT
Met235Thr
Exon 2
F: 5'-GAT GCG CAC AAG GTC 
CTG-3'
R: 5'-CAG GGT GCT GTC CAC 
ACT GGC TCG C-3'
302 57°C/BstUI/
T = 302
C = 278, 24
ACE
Ins/Del
Intron 16
F: 5'-CTG GAG ACC ACT CCC 
ATC CTT TCT-3'
R: 5'-GAT GTG GGC ATC ACA 
TTC GTC AGA T-3'
[Ref: Nucleic Acids Res. 1992, 
20: 1433]
490 Ins = 490
Del = 190
*AT1
A>C (-1166)
Promoter
F: 5'-AAG AAG CCT GCA CCA 
TGT TT-3'
R: 5'-CCA TCT TAC GGG CAT 
TGT TT-3'
626 58°C/Dde I/
A = 536, 90
C = 119, 417, 90
*AT1
A>T (-777)
Promoter
F: 5'-AGT CAC CCT ACT CAC 
CTA GCT AAC A-3'
R: 5'-AGA CAT CAC GAG ACT 
ACA GAT CAA-3'
192 60°C/Alu I/
A = 173 19
T = 192
*CYP11B2
T>C (-344)
Promoter
5'-TGG AGG GTG TAC CTG 
TGT GTC A-3'
5' GTC CTG CTG GTC TGA 
GGA TG3'
270 57°C/Hae III/
T = 189, 81
C = 118, 71, 81
*CMA
G>A (-1903)
Promoter
F: 5'-GGA AAT GTGAGC AGA 
TAG TGC AGT C-3'
R: 5'-AAT CCG GAGCTG GAG 
AAC TCT TGTC-3'
285 55°C/BstXI/
G = 195, 90
A = 285
*CMA
C>T (-1777)
Promoter
F: 5'-ATA TCA GTG AAA GCA 
AAC AGC TT-3'
F: 5'-TAA GTG CCT TTC CCA 
AAT CA-3'
555 60°C/Mnl I/
C = 54, 501
T = 555
* Primers for these SNPs are designed in this study
** Alleles of the tetra nucleotide repeat (ACAG)n are resolved on PAGE and denoted as 1,2,3, 4 and 5.BMC Medical Genetics 2006, 7:42 http://www.biomedcentral.com/1471-2350/7/42
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tocols to ensure standardization. Glomerular filtration
rate (GFR) was estimated by using online Cockcroft-Gault
calculator [19]. For CRI, the inclusion criteria were sub-
jects with Type 2 diabetes for ≥2 years, serum creatinine ≥3
mg/dl, urinary albumin excretion rate (AER) > 200 mg/l
and presence of diabetic retinopathy. Patients with drug
induced nephrotoxic damage or secondary causes of albu-
minuria such as obstructive renal disease, renal stone dis-
ease and acute urinary tract infection were excluded from
this group. Normoalbuminuric (AER < 20 mg/l) Type 2
diabetes subjects of ≥10 years duration of diabetes (aver-
age 17.07 ± 6.69 years) were recruited as control diabetes
subjects. Normoalbuminuria among control (DM) sub-
jects was determined by timed urine collections. An aliq-
uot of blood from the four centres was transported to the
genetic laboratory (BKT) for DNA isolation. DNA was iso-
lated from the lymphocytes using the conventional phe-
nol-chloroform organic extraction method [20] and used
for genetic analysis.
Genetic analysis
Twelve polymorphisms from six genes namely REN, AGT,
ACE, CMA, AT1 and CYP11B2, were chosen for genotyp-
ing using the polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) approach,
details of which are presented in Table 1. The choice of
these SNPs was based on either their functional status or
their widely analysed status. Primers were designed using
Primer 3 software [21]. The digested PCR products were
resolved on 2–3% agarose gel stained with ethidium bro-
mide. Genotype configurations of each of the SNPs are
also presented in this table.
Statistical analysis
All the statistical tests were done using the SPSS version
11.0. Discrete and continuous variables were compared
between cases (CRI) and controls (DM) using Pearson's χ2
test and unpaired t-test as appropriate. Parameters with
skewed distribution (diastolic and systolic blood pressure,
and serum creatinine) are presented as median and range
and compared using Mann-Whitney U test. Hardy-Wein-
berg equilibrium was tested for each of the SNPs based on
the genotyping of 440 chromosomes from normal
healthy individuals (average age 35.11 ± 8.98 years).
These were recruited on a random basis from different
locations including public meeting places, offices, col-
leges, markets and hospitals and represent population
based controls. Pearson's χ2 test (3 × 2 contingency table)
was used to assess association of SNPs with renal disease
using the cases (CRI) and controls (DM). Allelic and gen-
otypic associations of SNPs found significant by Pearson's
χ2 test were evaluated by computing odds ratio (O.R.) and
95% confidence intervals (CI). Power of the sample size
for each of the SNPs was calculated using PAWE software
version 1.2 [22,23]. Haplotype analysis was performed
using PHASE-standard analysis version 2.0.2 [24,25]. Chi-
square values were derived from a series of 2 × 2 contin-
gency tables based on the frequency of each haplotype
versus all others between the diabetes (DM) and the CRI
groups. Logistic regression analysis was carried out to cor-
relate various clinical parameters with genotypes and to
study pair wise interactions between SNPs of different
genes. P values were subject to Bonferroni's correction and
considered significant when <0.05.
Table 2: Clinical characteristics of the study population
Characteristics DMa (N = 225) CRIb (N = 196) P
Gender (M/F) 76/149 65/131 0.89d
Age (years) 60.6 ± 11.5 57 ± 12.8 0.10c
Duration of Diabetes (years) 17.07 ± 6.69 10.4 ± 7.7 <0.05c
Hb A1c(%) 7.3 ± 1.0 7.5 ± 1.1 0.949c
Systolic pressure (mm Hg) * 140 (106–190) 150 (110–210) 0.002e
Diastolic pressure (mm Hg) * 84 (80–104) 90 (70–110) 0.025e
Serum creatinine (µmol/l) * 84 (35–108) 177 (124–1112) <<0.05e
UAER (mg/l) * 10 (1–16) 864 (320–1584) <<0.05e
GFR (mls/min/1.73 m2) 81.44 ± 21.85 27.83 ± 24 <<0.05c
Serum triglyceride (mmol/l) 1.7 ± 0.67 1.8 ± 1.4 0.307c
Serum cholesterol (mmol/l) 4.8 ± 0.97 4.9 ± 0.92 0.852c
Retinopathy (%)
Non proliferative (%)
Proliferative (%)
24
15
8.6
88
35
53
<<0.05d
Cardiovascular events (%) 3 8.3
Data presented as mean ± SD (* median and range). a type 2 diabetes subjects without nephropathy (DM); b with diabetic renal insufficiency (CRI); c 
Student's t test; d Pearson's χ2 test; e Mann-Whitney U test.BMC Medical Genetics 2006, 7:42 http://www.biomedcentral.com/1471-2350/7/42
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Results
Clinical analysis
Demographic and clinical details of the subjects included
in the study are given in Table 2. Total number of males as
compared to females was more in both diabetes mellitus
(DM) and CRI groups but male to female ratio between
the two groups was not significantly different. No signifi-
cant difference was observed in body-mass index, glycated
hemoglobin (HbA1c), total serum cholesterol and triglyc-
eride between the DM and CRI groups (P > 0.05). Serum
creatinine, diastolic and systolic pressure, proportion of
hypertensive individuals, and those with diabetic retinop-
athy were significantly higher (P < 0.05) among CRI sub-
jects as compared to controls (Table 2).
Genetic analysis
Glu53Stop, a nonsense mutation in AGT gene and A>T (-
777) SNP in AT1 gene were found to be monomorphic in
Table 3: Allele and genotype frequencies of SNPs and their association status with diabetic chronic renal insufficiency.
SNPs Allele frequency Genotype frequency Association
DM CRI DM CRI Allele (df = 1) Genotype (df = 2)
REN
C>T (-4063)
C = 0.85 C = 0.84 CC = 0.73 CC = 0.72 χ2 = 1.01, P = 0.60 χ2 = 0.29, P = 0.59
T = 0.15 T = 0.16 CT = 0.24 CT = 0.23
TT = 0.03 TT = 0.05
REN
(ACAG)n
1 = 0.80 1 = 0.81 11 = 0.64 11 = 0.67 χ2 = 8.56, P = 0.38 
(df = 4)
χ2 = 4.55, P = 0.34 (df 
= 8)
2 = 0.10 2 = 0.105 12 = 0.155 12 = 0.14
3 = 0.09 3 = 0.07 13 = 0.155 13 = 0.10
4 = 0.01 4 = 0.016 14 = 0.02 14 = 0.026
5 = 0.00 5 = 0.005 22 = 0.01 22 = 0.02
23 = 0.02 23 = 0.02
33 = 0.00 24 = 0.005
33 = 0.01
55 = 0.005
AGT
A>G (-6)
G = 0.46 G = 0.41 GG = 0.32 GG = 0.24 χ2 = 2.21, P = 0.14 χ2 = 3.38, P = 0.18
A = 0.54 A = 0.59 GA = 0.28 GA = 0.34
AA = 0.40 AA = 0.42
AGT
Thr174Met
C = 0.90 C = 0.87 CC = 0.81 CC = 0.76 χ2 = 1.32, P = 0.25 χ2 = 1.48, P = 0.48
T = 0.10 T = 0.13 CT = 0.18 CT = 0.23
TT = 0.01 TT = 0.01
AGT
Met235Thr
T = 0.61 T = 0.37 TT = 0.42 TT = 0.16 χ2 = 46.41, P << 
0.01
χ2 = 39.2, P << 0.01
C = 0.39 C = 0.63 TC = 0.38 TC = 0.42
CC = 0.20 CC = 0.42
ACE
Ins/Del
Ins = 0.56
Del = 0.44
Ins = 0.53
Del = 0.47
Ins/Ins = 0.34
Ins/Del = 0.43
Del/Del = 0.23
Ins/Ins = 0.34
Ins/Del = 0.38
Del/Del = 0.28
χ2 = 0.76, P = 0.38 χ2 = 1.60, P = 0.45
AT1
A>C (-1166)
A = 0.93 A = 0.93 AA = 0.86 AA = 0.86 χ2 = 0.08, P = 0.78 χ2 = 0.20, P = 0.90
C = 0.07 C = 0.07 AC = 0.13 AC = 0.11
CC = 0.01 CC = 0.01
CYP11B2
T>C (-344)
T = 0.64 T = 0.73 TT = 0.40 TT = 0.54 χ2 = 8.54, P = 
0.003
χ2 = 0.84, P = 0.01
C = 0.36 C = 0.27 T C = 0.47 T C = 0.38
CC = 0.13 CC = 0.08
CMA
G>A (-1903)
G = 0.57 G = 0.52 GG = 0.27 GG = 0.13 χ2 = 2.51, P = 0.11 χ2 = 12.5, P = 0.002
A = 0.43 A = 0.48 GA = 0.62 GA = 0.77
AA = 0.12 AA = 0.10
CMA
C>T (-1777)
C = 0.68 C = 0.71 CC = 0.49 CC = 0.50 χ2 = 0.88, P = 0.35 χ2 = 4.24, P = 0.12
T = 0.32 T = 0.29 CT = 0.38 CT = 0.43
TT = 0.13 TT = 0.07BMC Medical Genetics 2006, 7:42 http://www.biomedcentral.com/1471-2350/7/42
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our population and therefore not analysed further. Allele
and genotype frequencies of the other ten SNPs along
with their association status are presented in Table 3. We
observed a highly significant association (P < 0.01) of
Met235Thr SNP in AGT gene and odds ratio calculations
identified Thr allele and Thr/Thr genotype to be predis-
posing to CRI (O.R. 2.68, 95%CI: 2.01–3.57 for Thr allele,
O.R. 2.94, 95%CI: 1.88–4.59 for Thr/Thr genotype). A
strong association of T allele (O.R. 1.57, 95%CI: 1.16–
2.14) and TT genotype (O.R. 1.81, 95%CI: 1.21–2.71) of
T>C -344 SNP of CYP11B2 gene and GA genotype (O.R.
2.06, 95%CI: 1.34–3.71) of G>A (-1903) promoter SNP
of CMA gene was also observed in our sample set. A large
number of haplotypes for AGT gene were generated and
are presented in Table 4. Haplotype G-C-T (G-6 – Thr174
– Met235) was seen to be predominant among the total
sample set (37% among DM and 31% among CRI) ana-
lysed in this study. Only two haplotypes A-C-C (A-6 –
Thr174 – Thr235) and A-C-T (A-6 – Thr174 – Met235)
were significantly associated (after multiple corrections)
with CRI (χ2 = 40.83, P < 0.01; χ2 = 47.38, P < 0.01 respec-
tively) and were found to be the predisposing and protec-
tive haplotypes respectively (Table 4).
In a multiple logistic regression analysis (backward step-
wise logistic regression method) using DM or CRI status
as a dependent variable, we observed a significant associ-
ation of Met235Thr polymorphism with CRI (P < 0.01)
and Thr/Thr genotype (O.R. 1.54, 95%CI: 1.03–2.04) was
found to be highly predisposing supporting the results
obtained from Pearson's χ2 test and odds ratio analysis.
Pair-wise interactions between different polymorphisms
included in this study were tested using multiple logistic
regression analysis. No significant interaction between
any of these polymorphisms/genes was observed.
Discussion
Considering that India leads the world with the highest
number of individuals affected with Type 2 diabetes very
little information on the genetic susceptibility to this
complex trait as well as to several of diabetes specific
micro- and macro-vascular complications among Indian
subjects is available. In this report on RAAS pathway
genes, we tested association of a total of twelve polymor-
phisms from exonic, intronic and promoter regions of six
genes with diabetic CRI using a case-control approach and
found significant associations of RAAS and chymase path-
way genes, viz., Met235Thr in angiotensinogen, T>C (-
344) in aldosterone synthase, and G>A (-1903) in chy-
mase genes.
There was no significant difference in either the gender
distribution or age in the two groups included in our
study. Duration of Type 2 diabetes was significantly differ-
ent between the two groups, with control diabetes group
having a longer duration, which ensured the choice of
appropriate controls in our study. Significantly higher
diastolic and systolic blood pressure, as well as higher per-
centage of diabetic retinopathy and cardiovascular disease
were observed among CRI subjects in our study (Table 2),
which is in conformity with common clinical observa-
tions in diabetic kidney disease [26-28].
There are a few study limitations. Firstly, the study
involves a small sample size. Harrington has commented
on standards of evidence in the genomic age and suggests
that in a case control study the sample size should be
>1000 subjects to arrive at worthwhile conclusions [29].
However, only a very few investigators have access to such
a large data and inspite of being a multi-site study the
present study could not achieve such large numbers. On
Table 4: Haplotypes of A>G (-6) – Thr174Met – Met235Thr SNPs in AGT gene tested for association with diabetic chronic renal 
insufficiency.
Haplotype* DM CRI χ2 P (df = 2) O.R. (95%CI)
nF r e q . nF r e q .
A-C-T 92 0.236 23 0.06 47.38 0.0000** 0.260 (1.27–
0.33)
A-C-C 93 0.24 174 0.45 16.99 0.0000** 1.93 (1.41–
2.65)
A-T-T 08 0.20 01 0.003 5.4 0.02 0.125 (0.015–
1.00)
A-T-C 16 0.04 30 0.08 4.76 0.029 1.98 (1.06–3.69)
G-C-T 144 0.37 118 0.31 3.32 0.068 0.758 (0.56–
1.02)
G-C-C 25 0.06 25 0.065 0.06 0.81 0.93 (0.52–1.67)
G-T-T 06 0.015 01 0.003 3.526 0.06 0.167 (0.02–
1.39)
G-T-C 06 0.015 14 0.036 3.14 0.076 2.34 (0.89–6.15)
* Order of SNPs in AGT haplotypes: A>G (-6) – Thr174Met – Met235Thr
** Significant after Bonferroni correction α = 0.006BMC Medical Genetics 2006, 7:42 http://www.biomedcentral.com/1471-2350/7/42
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the other hand the present study fulfils most of the criteria
of a good genetic association study suggested by Hatters-
ley et al [30]. Secondly, the diagnosis of diabetic renal dis-
ease in the present study is based on multiple criteria.
Diabetes can produce a large variety of renal lesions and it
is likely that molecular and genetic pathways involved in
each of these are different. In the present study all the
cases had moderate to severe CRI as indicated by creati-
nine of ≥3 mg/dl and involvement of various components
of RAAS pathway is clearly indicated in advanced diabetic
kidney disease by many previous studies. Thirdly, lack of
treatment details of the subjects is a minor limitation as
treatment with ACE inhibitors or ARBs do not influence
genetic polymorphisms.
Of the ten polymorphisms that were genotyped in the
study groups (Table 3), tetra nucleotide repeat (ACAG)n of
REN gene and SNPs A>G (-6) and Met235Thr of AGT gene
were not in Hardy-Weinberg-Equilibrium (HWE) in the
present study (data not shown). Higher rate of mutation/
variability of microsatellite marker(s) may provide a likely
explanation for deviation of (ACAG)n of REN gene from
HWE. The deviation of SNPs A>G (-6) and Met235Thr of
AGT gene may be due to significant excess of heterozy-
gotes of both the SNPs in our representative baseline con-
trol population, which could be attributed to yet
unknown selection pressure. We confirm that care was
taken to ensure random sampling of population based
controls and also error free genotyping as reported in pre-
vious studies from our group [31]. We did not observe
association of SNPs in three genes namely REN, ACE and
AT1 with CRI in our study. The results in renin gene is not
surprising since association of the two polymorphisms in
REN gene included in this study has not been reported so
far in any population. However, there are many reports on
association in AT1 [32-34] and ACE genes [35-38], which
are inconsistent across populations. The only other pub-
lished study on ACE ins/del polymorphism in diabetic
nephropathy subjects from India showed a significant
association of the del allele [39].
Met235Thr in AGT gene showed a very strong allelic, gen-
otypic and haplotypic association with CRI (Tables 3, 4).
This is quite in agreement with data from functional anal-
ysis of this molecular variant, where in Thr/Thr
homozygous individuals were shown to have elevated lev-
els of angiotensinogen which could then lead to increased
production of vasoconstrictor peptide Ang II in blood
plasma and kidney [12]. Contrary to an earlier observa-
tion [12] we neither observed a tight LD between
Met235Thr and the promoter SNP A>G (-6) of this gene
nor association of the promoter SNP with CRI. Our obser-
vation of independent contribution of Met235Thr to
development of CRI is further supported by our results of
haplotype analysis. Out of the two significantly associated
haplotypes, the haplotype A-C-C containing Thr235 is
predisposing to CRI (χ2 = 40.83; P << 0.01) and another
haplotype A-C-T- (A-6 – Thr174 – Met235), with only one
allele (Met235) different as compared to the predisposing
haplotype, is protective (χ2 = 47.38; P << 0.01) to CRI
(Table 4). It may be added here that haplotype association
observed in this study, is genuine and not caused by the
deviation of this marker from HWE, since any haplotype
analysis carried out using PHASE (Version 2.0.2) software
is not influenced by HWE. Multiple logistic regression
analysis results, which showed a very significant associa-
tion of only Met235Thr SNP and Thr235 allele even in the
presence of all other genetic and crucial clinical factors
analysed in the study, further underscores the involve-
ment of 235Thr allele. 41% of all CRI patients in our sam-
ple set possessed Thr/Thr genotype. Based on all these
observations, and considering the power of our sample (G
= 99%) we conclude that Thr235 could be a susceptibility
allele for CRI. The role of Met235Thr polymorphism in
the development of diabetic nephropathy and ESRD is
widely debated and published association studies present
inconsistent results [40-44].
SNP T>C-344 of aldosterone synthase gene was also
found to be significantly associated (P = 0.012) with CRI
in our sample set. Allele T and genotype TT of this SNPs
seems to be predisposing to kidney disease (O.R. 1.57;
95%CI: 1.16–2.14 and O.R. 1.81; 95%CI: 1.21–2.71
respectively) but we would be cautious of this association
due to the sub-optimal power of the sample (G = 40%).
Recent experimental evidences implicate aldosterone as
an important factor in pathogenesis of advanced diabetic
kidney disease independent of arterial blood pressure and
plasma Ang II levels [45]. In addition, it has been
observed that "aldosterone escape" observed in a propor-
tion of DN patients during blockade of RAAS is associated
with decline in glomerular filtration rate [46].
We also observed a significant association of G>A (-1903)
promoter SNP of chymase gene with CRI. No allelic asso-
ciation was observed but genotype GA seems to be highly
predisposing (O.R. 2.06; 95%CI: 1.34–3.17) to diabetic
renal disease. Chymase gene plays an important role in
Ang II production under conditions like diabetes mellitus
and glomerular hypertension. Considering such an
importance of CMA gene in renal function our observa-
tion of association of this promoter SNP in this gene
seems exciting but due to the low power of our sample (G
= 14%) this result needs to be replicated in larger sample
sets. However, the only other study on European popula-
tion, did not observe association of this SNP with DN
[47].
Pearson's χ2 test carried out to test the possibility of asso-
ciation of the polymorphisms analysed in this study withBMC Medical Genetics 2006, 7:42 http://www.biomedcentral.com/1471-2350/7/42
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hypertension (data not shown) showed no association.
This further confirmed the independent association of
Met235Thr, T>C (-344) and G>A (-1903) SNPs with CRI
and suggests that these SNPs though known to modulate
RAAS activity, does not operate through hypertension as a
crucial mechanism but via stimulation of chemokines like
TGF β1, TNF α and IL1 [48,49], thus warranting further
investigations of such genes.
Conclusion
Use of SNPs Met235Thr in angiotensinogen, T>C (-344)
in aldosterone synthase, and G>A (-1903) in chymase
genes for prediction of susceptibility to diabetes specific
renal disease in the Asian Indian population appears
promising. However, results from this pilot study not only
warrant replication in larger sample sets obtained from
multiple centres across the country but also investigations
on candidate gene polymorphisms from other biochemi-
cal pathways.
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